GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SpringWorks Therapeutics Inc (NAS:SWTX) » Definitions » Cash Flow from Investing

SpringWorks Therapeutics (SpringWorks Therapeutics) Cash Flow from Investing : $-42.39 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is SpringWorks Therapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, SpringWorks Therapeutics spent $0.58 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $73.64 Mil on purchasing investments. It gained $103.92 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $8.24 Mil for other investing activities. In all, SpringWorks Therapeutics gained $21.46 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


SpringWorks Therapeutics Cash Flow from Investing Historical Data

The historical data trend for SpringWorks Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SpringWorks Therapeutics Cash Flow from Investing Chart

SpringWorks Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial -4.26 -418.83 83.59 -215.60 34.75

SpringWorks Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.60 60.76 34.60 -159.21 21.46

SpringWorks Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

SpringWorks Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

SpringWorks Therapeutics's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SpringWorks Therapeutics  (NAS:SWTX) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

SpringWorks Therapeutics's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-0.58 Mil. It means SpringWorks Therapeutics spent $0.58 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

SpringWorks Therapeutics's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means SpringWorks Therapeutics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

SpringWorks Therapeutics's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means SpringWorks Therapeutics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

SpringWorks Therapeutics's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means SpringWorks Therapeutics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

SpringWorks Therapeutics's purchase of investment for the three months ended in Mar. 2024 was $-73.64 Mil. It means SpringWorks Therapeutics spent {stock_data.stock.currency_symbol}}73.64 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

SpringWorks Therapeutics's sale of investment for the three months ended in Mar. 2024 was $103.92 Mil. It means SpringWorks Therapeutics gained $103.92 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

SpringWorks Therapeutics's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means SpringWorks Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

SpringWorks Therapeutics's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means SpringWorks Therapeutics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

SpringWorks Therapeutics's cash from other investing activities for the three months ended in Mar. 2024 was $-8.24 Mil. It means SpringWorks Therapeutics paid $8.24 Mil for other investing activities.


SpringWorks Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of SpringWorks Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


SpringWorks Therapeutics (SpringWorks Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
100 Washington Boulevard, Stamford, CT, USA, 06902
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
Executives
Tai-an Lin officer: Chief Scientific Officer C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BOULEVARD, STAMFORD CT 06902
Julie Hambleton director C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Jeffrey Lawrence Schwartz director, 10 percent owner C/O BAIN CAPITAL LIFE SCIENCES, LP, 200 CLARENDON STRERET, BOSTON MA 02116
Daniel Pichl officer: Chief People Officer C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902
James Cassidy officer: Chief Medical Officer 368 NOD HILL ROAD, WILTON CT 06897
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carlos Alban director 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Saqib Islam director, officer: Chief Executive Officer ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
L. Mary Smith officer: See Remarks C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902
Bain Capital Life Sciences Investors, Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Michael F. Burgess officer: Head of Research & Development C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Stephen P Squinto director, 10 percent owner C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Bhavesh Ashar officer: Chief Commercial Officer C/O SPRINGWORKS THERAPEUTICS, 100 WASHINGTON BLVD, STAMFORD CT 05902
Orbimed Capital Gp Vi Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Badreddin Edris officer: Chief Business Officer C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902

SpringWorks Therapeutics (SpringWorks Therapeutics) Headlines

From GuruFocus

SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-03-2023

Nicholas Investment Partners, LP Buys 2, Sells 3 in 4th Quarter

By GuruFocus Research GuruFocus Editor 02-13-2023